Comparative Pharmacology
Head-to-head clinical analysis: AZOPT versus ETHAMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZOPT versus ETHAMIDE.
AZOPT vs ETHAMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Carbonic anhydrase inhibitor; inhibits carbonic anhydrase II (CA-II) in ciliary processes, reducing aqueous humor secretion and intraocular pressure.
Ethamide is a carbonic anhydrase inhibitor that reduces aqueous humor production in the eye, lowering intraocular pressure. It also has diuretic effects by inhibiting carbonic anhydrase in the proximal renal tubule, leading to bicarbonate excretion and metabolic acidosis.
One drop in the affected eye(s) twice daily. Instill at least 10 minutes apart from other ophthalmic medications.
15-25 mg/kg orally once daily (max 1.5 g/day).
None Documented
None Documented
Terminal elimination half-life is approximately 111 minutes (1.85 hours) in plasma after topical ocular administration; prolonged in renal impairment (creatinine clearance <30 mL/min).
Terminal elimination half-life is 4-6 hours in normal renal function; prolonged to 12-24 hours in severe renal impairment (CrCl <30 mL/min).
Primarily renal excretion as unchanged drug (approximately 70% of a topically applied dose is absorbed systemically and excreted unchanged in urine); minimal biliary/fecal elimination (<5%).
Primarily renal (80-90%) as unchanged drug via glomerular filtration and tubular secretion; minor biliary/fecal (<5%) and metabolic (5-10%) elimination.
Category C
Category C
Carbonic Anhydrase Inhibitor
Carbonic Anhydrase Inhibitor